All Press Releases for November 18, 2021

Entvantage Diagnostics gets listed on THE OCMX™

The OCMX™ is pleased to announce the listing of Entvantage Diagnostics to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.



    AUSTIN, TX, November 18, 2021 /24-7PressRelease/ -- ENTvantage Dx, based in Austin TX, is a clinical stage diagnostics company that provides physicians with rapid information on the underlying cause of upper respiratory illnesses.

The OCMX™ is pleased to announce the listing of Entvantage Diagnostics to its online portal which offers Investors and Advisors the ability to learn more about this exciting opportunity.

The OCMX™ has spent considerable time completing its due diligence on Entvantage Diagnostics and concluded that there is indeed a tremendous potential for this opportunity.

The OCMX™ noted that Entvantage Diagnostics exhibits the main components of any solid opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.

WHAT THEY DO

Entvantage Diagnostics has developed Sinu-Test®, its first rapid test product for bacterial sinusitis detection. The Sinu-Test Bacterial Sinusitis Test Kit includes a proprietary collection device and bacterial assay kit as a rapid, in-office diagnostic test for determination of bacterial sinusitis.

The first-of-its-kind, FDA Class II DeNovo Diagnostic test kit, with issued patents in the U.S., EU, Australia and Japan, provides primary care and ENT physicians with a simple and accurate point-of-care test for sinusitis that takes 20 minutes to achieve results and allows healthcare providers to determine the 10% of patients that have bacterial sinusitis and can benefit from antibiotics from the 90% that have viral sinusitis where antibiotics are ineffective. Clinical testing is underway in the U.S.

WHERE THEY ARE HEADED

Entvantage Diagnostics has commenced multi-centered clinical trials in the U.S. to gain FDA 510(k) clearance for its Sinu-Test product.

In addition, the company plans to extend the indications for its assay from sinusitis to acute bronchitis indication. Finally, the company will commence early commercialization activities in preparation for the launch of the Sinu-Test product.

OPPORTUNITY HIGHLIGHTS

• First to market opportunity for bacterial sinusitis assay.
• Strong issued patent portfolio in all major territories
• Large unmet market opportunity with a point-of-care diagnostic product
• U.S. reimbursement in place using existing CPT reimbursement codes
• Can increase physician revenue and reduce the overall cost of treatment of upper respiratory illnesses

MANAGEMENT TEAM

Joseph Skraba, President and CEO
Joe has spent his entire career in medical product development and management. He holds a Bachelor's Degree in Mechanical Engineering, a Master's in Technology Commercialization and an MBA.

Oriana Hawkins, PhD, Director of Assay Development
Oriana has been with the project since its onset. Oriana holds a PhD in Immunology and Microbiology from the University of Oklahoma and completed a Post-Doc assignment at Vanderbilt University.

Elisa Maldonado Holmertz, Director of Clinical/Regulatory and Quality
Elisa has been associated with Entvantage since 2017. Elisa holds a B.A. in Biology from The University of Texas at Austin and has worked her whole career in medical device and pharmaceutical industry. She has worked in the regulatory field and lived on 4 continents during her professional career.

ABOUT THE OCMX™

The OCMX™ is changing how companies generate exposure in the financial marketplace and raise funds as we know it. The OCMX™ serves both public and private companies in need of market exposure during financial raises. It does this by way of connecting the relevant companies with financial institutions all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors.

The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
The OCMX™
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

Entvantage Diagnostics gets listed on THE OCMX™
Listing Page link

# # #

Contact Information

David Clarke
OCMX
Toronto, Ontario
Canada
Voice: 866-206-6862
E-Mail: Email Us Here